Company Overview and News
Watertown, Mass.-based Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage trial that showed a significant reduction of serum uric acid at 12 weeks.
It has been about a month since the last earnings report for Horizon Pharma Public Limited Company (HZNP - Free Report) . Shares have added about 18.3% in that time frame.
73640QAB1 UNP PRAA HZNP
Every day the opioid epidemic is destroying lives and communities across the country. Dr. Jeremy Levin, chairman and CEO of Ovid Therapeutics, serves as chair of BIO’s working group on opioids. In an op-ed published earlier this year by Morning Consult, Dr. Levin wrote:
Horizon Pharma and the National Organization for Rare Disorders (NORD) launched a new campaign today that recognizes innovation in rare disease therapeutics since the passing of the Orphan Drug Act in 1983. Starting today, a display will be placed in the main lobby of the 2018 Biotechnology Innovation Organization (BIO) International Convention in Boston.
Kitov Pharma Ltd. (KTOV - Free Report) announced today that the FDA has approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
LGNZZ LGND LGNYZ LGNXZ HZNP PFE LGNDZ
DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that it has been selected to FORTUNE and Great Place to Work’s 2018 “Best Workplaces in Chicago” list. Horizon ranked number four out of 25 other small and medium sized companies.
DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today marked Gout Awareness Day with the launch of Gout Revealed, which was created to spotlight real-life stories of people living with uncontrolled gout, a painful and debilitating inflammatory form of arthritis caused by too much uric acid in the blood that continues despite the use of oral medicines. The site features people sharing their experiences with the disease – from the impact of the pain and the moments of life missed, to finally speaking with a gout specialist to help manage their condition.
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
SNI BGX DISCB VST DISCA TSU TWX AU DISCK ENL BGLF STAY SHPG VIAB HAWK AABA DST OSG.WI SSNC AEM INSW AGG SYMX AET DISC FOX TMUSP TMUS RGORF VRX BKD UTX GOLD BX 2840 TWC OGISD NSW OGSRW MDT BGB SGYP SES CZR OGSWW OGISZ XLGLF SCMP QCOM INSW.WI FOXA OGSBW ENDP NMRK NXPI XL CTL RRS GLD AULGF OSG VRX MYL AGN ODP EGN MON SGYPW HZNP OSGB DISH OVSPW CACQ COL GOLD OVSPA VST.WSA OAS T OVSPD VSTE MNK THM
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
Horizon Pharma plc (HZNP - Free Report) reported lower-than-expected results for the first quarter of 2018. Following the news, the company’s shares went down 5.6%. Horizon Pharma’s stock has declined 5.4% year to date compared with the industry’s fall of 12.3%.
The following slide deck was published by Horizon Pharma plc in conjunction with their 2018 Q1 earnings call.
Good morning, and thank you for standing by. Welcome to the Horizon Pharma plc First Quarter 2018 Earnings Conference Call. As a reminder, today's conference call is being recorded.
MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS HZNP MS.PRA
Dublin, Ireland-based Horizon Pharma plc (HZNP - Free Report) is a biopharmaceutical focused on identifying, developing, acquiring and commercializing products that address unmet therapeutic needs in arthritis, pain, inflammatory and orphan diseases.
BUSE ESNT HZNP BMI
12h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
13h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET